Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Xact Kapitalforvaltning AB

Share on StockTwits

Xact Kapitalforvaltning AB increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.1% in the 1st quarter, HoldingsChannel reports. The fund owned 77,479 shares of the medical research company’s stock after purchasing an additional 2,357 shares during the period. Xact Kapitalforvaltning AB’s holdings in Thermo Fisher Scientific were worth $21,208,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Parallel Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 4.4% during the 1st quarter. Parallel Advisors LLC now owns 9,416 shares of the medical research company’s stock valued at $2,578,000 after acquiring an additional 393 shares during the last quarter. CX Institutional acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $36,000. Freestone Capital Holdings LLC increased its holdings in shares of Thermo Fisher Scientific by 46.1% during the 4th quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock valued at $2,256,000 after acquiring an additional 3,180 shares during the last quarter. Buckingham Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific by 6.9% during the 1st quarter. Buckingham Asset Management LLC now owns 2,106 shares of the medical research company’s stock valued at $576,000 after acquiring an additional 136 shares during the last quarter. Finally, HighPoint Advisor Group LLC increased its holdings in shares of Thermo Fisher Scientific by 14.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 2,918 shares of the medical research company’s stock valued at $793,000 after acquiring an additional 377 shares during the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.

TMO traded down $1.04 during midday trading on Friday, reaching $285.20. The company’s stock had a trading volume of 468,162 shares, compared to its average volume of 1,332,870. The firm has a market capitalization of $114.08 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.87 and a beta of 1.08. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. Thermo Fisher Scientific Inc. has a twelve month low of $202.83 and a twelve month high of $288.07.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.07. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. The company’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.50 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 12.2 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, June 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now owns 6,433 shares in the company, valued at approximately $1,741,606.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the sale, the chief financial officer now owns 40,029 shares of the company’s stock, valued at approximately $10,739,380.41. The disclosure for this sale can be found here. Insiders sold a total of 53,488 shares of company stock worth $14,600,474 in the last ninety days. Insiders own 0.45% of the company’s stock.

A number of brokerages have recently commented on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price objective on the stock in a report on Wednesday. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Thursday, May 30th. They set an “outperform” rating on the stock. Needham & Company LLC reissued a “strong-buy” rating and set a $315.00 price objective (up previously from $313.00) on shares of Thermo Fisher Scientific in a report on Thursday, May 23rd. BTIG Research increased their price objective on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Finally, UBS Group increased their price objective on Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $295.92.

ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Xact Kapitalforvaltning AB” was posted by Zolmax and is the sole property of of Zolmax. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://zolmax.com/investing/thermo-fisher-scientific-inc-nysetmo-shares-bought-by-xact-kapitalforvaltning-ab/3114310.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Holder of Record

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Synergy Resources Corporation  Expected to Announce Quarterly Sales of $194.53 Million
Synergy Resources Corporation Expected to Announce Quarterly Sales of $194.53 Million
Jumia Technologies AG –  Expected to Announce Quarterly Sales of $39.19 Million
Jumia Technologies AG – Expected to Announce Quarterly Sales of $39.19 Million
Zacks: Brokerages Expect Encore Capital Group, Inc.  Will Announce Quarterly Sales of $356.84 Million
Zacks: Brokerages Expect Encore Capital Group, Inc. Will Announce Quarterly Sales of $356.84 Million
Zacks: Brokerages Expect Ferro Co.  Will Announce Quarterly Sales of $425.53 Million
Zacks: Brokerages Expect Ferro Co. Will Announce Quarterly Sales of $425.53 Million
Global Medical REIT Inc  Expected to Post Quarterly Sales of $16.74 Million
Global Medical REIT Inc Expected to Post Quarterly Sales of $16.74 Million
Icon Plc  Given Consensus Rating of “Buy” by Brokerages
Icon Plc Given Consensus Rating of “Buy” by Brokerages


 
© 2006-2019 Zolmax.